Literature DB >> 18301075

Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation.

Ana Moreno, Rafael Bárcena, Carmen Quereda, José L Casado, María J Pérez-Elías, Jesús Fortún, Javier Nuño, Isabel Arranz, Santiago Moreno.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18301075     DOI： 10.1097/QAD.0b013e3282f37478

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  9 in total

Review 1.  HIV-1 immunopathogenesis in humanized mouse models.

Authors:  Liguo Zhang; Lishan Su
Journal:  Cell Mol Immunol       Date:  2012-04-16       Impact factor: 11.530

Review 2.  Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis.

Authors:  LiGuo Zhang; Eric Meissner; JianZhu Chen; LiShan Su
Journal:  Sci China Life Sci       Date:  2010-03-07       Impact factor: 6.038

Review 3.  Renal dysfunction in the setting of HIV/AIDS.

Authors:  Jose M Miro; Federico Cofan; Joan C Trullas; Christian Manzardo; Carlos Cervera; Montserrat Tuset; Federico Oppenheimer; Mercedes Brunet; Asuncion Moreno; Josep M Campistol; Jose M Gatell
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

Review 4.  Potential use of rapamycin in HIV infection.

Authors:  Marco Donia; James A McCubrey; Klaus Bendtzen; Ferdinando Nicoletti
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

5.  A Simplified HAART Regimen with Raltegravir and Lamivudine, and Pharmacokinetic Interactions with a Combined Immunosuppressive Therapy with Tacrolimus and Everolimus in an HIV/HCV/HBV/HDV Patient after Liver Transplantation.

Authors:  O Cirioni; L E Weimer; V Fragola; A Giacometti; F Ancarani; M Maracci; E Gabrielli; E Marchionni; M F Pirillo; S Vella
Journal:  West Indian Med J       Date:  2013-09-03       Impact factor: 0.171

6.  Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines.

Authors:  Anita Rachlis; Jonathan B Angel; Marianne Harris; Stephen D Shafran; Rachel Therrien; Cécile Tremblay; Mark A Wainberg
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

7.  Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.

Authors:  Alonso Heredia; Olga Latinovic; Robert C Gallo; Gregory Melikyan; Marv Reitz; Nhut Le; Robert R Redfield
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

Review 8.  Raltegravir use in special populations.

Authors:  Margaret Johnson
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175

Review 9.  HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?

Authors:  Martin Vogel; Mark Nelson
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.